Cargando…
Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
Greater understanding of the hepatitis C virus (HCV) genome and life cycle of the HCV virion allows for new targets for therapy that directly act on the viral machinery to inhibit replication. Numerous direct-acting antivirals are in development, and four have been brought to market. Simeprevir, a s...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976205/ https://www.ncbi.nlm.nih.gov/pubmed/24729731 http://dx.doi.org/10.2147/DHPS.S43304 |